https://ijmri.de/index.php/jmsi
volume 4, issue 4, 2025
1214
IMMUNOLOGICAL MECHANISMS
IN NAFLD
Khamidоva M.I.
Department of Gospital therapy and Endocrinology
Assistant
,
Andijan State Medical Institute.
Abstract:
The pandemics of coronavirus affliction 2019 (COVID-19) and non-alcoholic roly-
poly liver affliction (NAFLD) coexist. High-minded liver assistance examinations are patronise
in COVID-19 and hawthorn consequence liver destruction in NAFLD, preexisting liver
destruction from NAFLD hawthorn consequence the progression of COVID-19. On the other
hand the prognostication appropriateness of this interaction, though, is unclear. Corpulence is a
jeopardy factor for the formal propinquity of NAFLD extremely as a terrible progression of
COVID-19. squadron studies communicate self-contradictory consequences with reference to the
consequence of NAFLD formal propinquity on COVID-19 unwellness severity. awe-inspiring
molecular similarities of cytokine pathways in both diseases, including postacute sequelae of
COVID-19, indicate characteristic pathways for long-standing low-activity inflammation. This
another look testament summarise existing collections with reference to the interplay of both
afflictions and compare notes accomplishable contrivances of the consequence of individual
affliction on the other.
Key words:
COVID-19, inflammation, NAFLD, cytokine, liver disease.
NAFLD is a noncommunicable affliction whose widespread spread out diffuse upon be
contingent on people’s lifestyle, exceptionally dietetical habits, COVID-19 has an discriminating
progression outstanding to its individualism as an transmissible disease. This show the way to
undulations of communication that chalk up prompted widespread hygiene countermeasures to
incorporate the infection, exceptionally in the yesteryear 2 second childhood (2020 and 2021).
Lockdowns chalk up occurred in numerous nations to confine the mobility of general public and
in this manner anticipate the spread out diffuse of the coronavirus[1,2]. The disagreeable
isolation and lockdown magnitudes in the yesteryear 2 second childhood underneath the
bounteous infective preceding modifications had substantial sociological and intellectual effects.
in this manner in augmentation to the orchestrate viral consequences of COVID-19 on the liver,
thither are furthermore allusive consequences on the liver or liver disease, which hawthorn
amuse oneself an far-reaching impersonation in the extremely exploitation of these diseases. As
COVID-19 buoy all the more consideration renewed lockdowns and isolation magnitudes in the
looked toward for case history when bounteous deadly modifications originate contrariwise or
outstanding to freshly rising transmissible diseases, much consequences should furthermore be
sculptured and appropriated into explanation in the future. Numerous studies have indicated that
a notable proportion of COVID-19 patients admitted to hospitals have underlying conditions
such as hypertension, type 2 diabetes mellitus (T2DM), and cardiovascular disease (CVD),
which may increase the risk of mortality from the virus[3]. Non-alcoholic fatty liver disease
(NAFLD) is a multifaceted disorder characterized by the pathological accumulation of fat in
hepatocytes, occurring in the absence of significant alcohol consumption, is closely associated
with T2DM and CVD[4,5]. The diagnosis of NAFLD typically involves a comprehensive
evaluation, including imaging modalities such as ultrasound, computed tomography (CT), or
magnetic resonance imaging, alongside liver biopsies for histological confirmation[6]. The
https://ijmri.de/index.php/jmsi
volume 4, issue 4, 2025
1215
escalating global burden of obesity has substantially fueled the increasing prevalence and
incidence rates of NAFLD. Presently, NAFLD stands as one of the most common chronic liver
diseases globally, affecting approximately 30% of the world’s population. Recent medical
research has placed considerable emphasis on investigating the association between
NAFLD/metabolic-associated fatty liver disease (MAFLD) and COVID-19. A growing div of
evidence indicates that individuals with NAFLD face an elevated risk of experiencing severe
manifestations of COVID-19, resulting in poorer clinical prognosis[7]. This systematic review
expands the discussion by examining the effects of NAFLD on COVID-19 patients, addressing a
significant
gap
in
existing
literature
It has been established that NAFLD patients have background low-activity inflammation. This
phenomenon is maintained by the activation of stellate cells and cytokine production by Kupffer
cells, with IL-1β, TNF-α, interferon-γ, IL-6, and reactive oxygen species serving as characteristic
pro-inflammatory markers in the disease, ultimately inducing fibrotic changes[6]. Interestingly,
during the acute response of COVID-19 infection, similar inflammatory cytokines and markers
are raised, potentially responsible for the worsening of clinical markers in NAFLD patients[5].
The elevated immune response in such patients may chronically persist as sequelae, explaining
the slower recovery duration and readmission rates observed among the studies. Thus, low-
activity inflammation of NAFLD is assumed to be amplified during the acute-phase response of
COVID-19 infection, highlighting the interaction of the two diseases at a molecular level.
Several clinical implications may be inferred from our systematic review’s results and literature
search. Despite the independent association of mortality with concomitant NAFLD and COVID-
19 illness; the worsened in-hospital outcomes remain significant nonetheless. In light of this,
hospitalists are encouraged to provide greater care to patients with liver dysfunction, especially
NAFLD or MAFLD. Additionally, the potential for drug-drug interactions or drug toxicities
presents a notable challenge in the management of such patients[7]. Thus, clinicians are advised
to exercise vigilance with respect to monitoring liver function tests and drug dosages to avoid the
risk of developing hepatotoxicity. The commonly used combination of lopinavir/ritonavir should
be maximally avoided due to the alarming level of hepatotoxicity observed in COVID-19
patients while providing no significant benefit on the molecular level. This calls for tailored
strategies for NAFLD patients infected with COVID-19, in which drug recommendations,
guidelines, and dosages need to be further researched and adjusted. The tendency for poorer
outcomes also calls for greater vaccination efforts in the respective population, where patients
with NAFLD (or any other gastrointestinal-related illness) should receive priority for COVID-19
vaccination and booster shots. Moreover, to curb the potentially worsening clinical parameters of
NAFLD patients, it is strongly advised to engage in comprehensive multidisciplinary
coordination through a team of pulmonologists and hepatologists to optimize the management
and outcomes of such patients. Long-term complications of concomitant NAFLD and COVID-19
have not been clearly identified; thus, regular follow-up with a multidisciplinary team is essential
for surveillance and monitoring for new changes or worsening hepatic function in NAFLD
patients. Certain developments are strongly encouraged to arrive at a sustainable conclusion
regarding the influence of NAFLD on COVID-19-related endpoints. First, the publication of
global longitudinal data is important in evaluating robust trends and patterns in outcomes and
identifying hotspots that may be disproportionately impacted. Additionally, future prospective
observational or randomized studies are preferred due to their relatively lower risk of biases in
light of the current conflicting evidence[8]. Second, the discovery of novel biomarkers with
prognostic significance can serve as an indispensable tool for clinicians in creating an optimal
and personalized management strategy and predicting disease severity. Thirdly, additional
research on the impact of different therapeutic regimens on the outcome of concomitant NAFLD
and COVID-19 is essential, as current literature is unable to reveal sufficient research into novel
biomarkers. Finally, research into the social determinants (via regional, ethnic, and
socioeconomic analyses) is necessary to implement timely interventions and appropriate policy-
making, as Younossi et al[9] revealed an interesting increase in prevalence in Hispanic patients.
https://ijmri.de/index.php/jmsi
volume 4, issue 4, 2025
1216
In contrast, a greater mortality rate was observed in white patients, potentially setting the stage
for future studies that provide greater insights into the impact of race or ethnicity on NAFLD
outcomes. NAFLD affects a heterogeneous patient population. Although the primary driver in
many patients is metabolic syndrome, a complex and dynamic heterogeneous interaction of
different factors are involved. This another look was not accomplished to make clear reason
the partnership between NAFLD/MAFLD and COVID-19 was seen.
References
1.Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and
Treatment of Coronavirus (COVID-19).
2.Ashmore P, Sherwood E. An overview of COVID-19 global epidemiology and discussion of
potential drivers of variable global pandemic impacts. J Antimicrob Chemother. 2023;78:ii2-
ii11.
3.de Almeida-Pititto B, Dualib PM, Zajdenverg L, Dantas JR, de Souza FD, Rodacki
M, Bertoluci MC; Brazilian Diabetes Society Study Group (SBD). Severity and mortality of
COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis.
Diabetol Metab Syndr. 2020;12:75.
4.Han SK, Baik SK, Kim MY. Non-alcoholic fatty liver disease: Definition and subtypes. Clin
Mol Hepatol. 2023;29:S5-S16.
5.Moore JB. COVID-19, childhood obesity, and NAFLD: colliding pandemics. Lancet
Gastroenterol Hepatol. 2022;7:499–501. doi: 10.1016/S2468-1253(22)00100-5
6.Weiß J, Rau M, Geier A. Non-alcoholic fatty liver disease: epidemiology, clinical course,
investigation,
and
treatment.
Dtsch
Arztebl
Int.
2014;111:447–452.
doi:
10.3238/arztebl.2014.0447
7.Mouries J, Brescia P, Silvestri A, Spadoni I, Sorribas M, Wiest R, Mileti E, Galbiati M,
Invernizzi P, Adorini L, Penna G, Rescigno M. Microbiota-driven gut vascular barrier disruption
is a prerequisite for non-alcoholic steatohepatitis development. J Hepatol. 2019;71:1216–1228.
doi: 10.1016/j.jhep.2019.08.005
8.Adolph TE, Grander C, Grabherr F, Tilg H. Adipokines and Non-Alcoholic Fatty Liver
Disease: Multiple Interactions. Int J Mol Sci. 2017;18 doi: 10.3390/ijms18081649
9.Geng Y, Faber KN, de Meijer VE, Blokzijl H, Moshage H. How does hepatic lipid
accumulation lead to lipotoxicity in non-alcoholic fatty liver disease? Hepatol Int. 2021;15:21–
35. doi: 10.1007/s12072-020-10121-2
